Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Director | November 01, 2023 | November 03, 2023 |
| NeuBase Therapeutics, Inc.NBSE · Entity 109568 | Director | September 09, 2022 | September 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Matinas BioPharma Holdings, Inc.
Report date November 01, 2023 · Filed November 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2033-11-01 | Direct | 437,244 |
Reported balance
After 2023-11-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-01 · Grant · Acquired 437,244 · Balance 437,244 F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.
NeuBase Therapeutics, Inc.
Report date September 09, 2022 · Filed September 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2032-09-09 | Direct | 37,600 |
Reported balance
After 2022-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-09 · Grant · Acquired 37,600 · Balance 37,600 F1: 25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVADEL PHARMACEUTICALS PLC
Report date February 12, 2026 · Filed February 12, 2026
Section 16 reporting ended · disclosed 2026-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Disposition to issuer · Disposed 219,905 · Balance 0 F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F3: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.49 · Expires 2029-05-22 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-12 · Disposition to issuer · Disposed 8,057 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2029-08-07 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-12 · Disposition to issuer · Disposed 60,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.48 · Expires 2030-08-07 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.07 · Expires 2031-08-03 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.79 · Expires 2032-08-03 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.10 · Expires 2033-08-01 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-12 · Disposition to issuer · Disposed 33,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 · Expires 2034-07-30 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-12 · Disposition to issuer · Disposed 11,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.83 · Expires 2035-07-29 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-12 · Disposition to issuer · Disposed 11,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.
F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR").
F3: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1.
F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).
PROGENICS PHARMACEUTICALS INC
Report date June 19, 2020 · Filed June 23, 2020
Section 16 reporting ended · disclosed 2020-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.01 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-19 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. F2: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.01 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-19 · Disposition to issuer · Disposed 16,393 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect.
F2: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2019 Filed May 24, 2019 16:08 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantADSs | 27,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012076 · doc1.xml · nonDerivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,900 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · shares: Represents 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 01/31/2019; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 16:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 15,022 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000017 · ownership.xml · nonDerivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,091 F1 · shares: On December 31, 2018, the Reporting Person was issued 15,022 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 08:16 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 128,299 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-18-000907 · ownership.xml · derivative · entry 2 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,299 Underlying: Common Stock · 128,299 shares Expires 2028-10-31 Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 08:16 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 128,299 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-18-000907 · ownership.xml · derivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,299 Underlying: Common Stock · 128,299 shares Expires 2028-10-31 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 16:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 9,715 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000821 · matinasbiofm4_oct12018.xml · nonDerivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,069 F1 · shares: On October 1, 2018, the Reporting Person was granted 9,715 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. F1 · price: On October 1, 2018, the Reporting Person was granted 9,715 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 29, 2018 Filed Jul 11, 2018 16:23 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 20,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000620 · ende-matinas_fm4jun292018.xml · nonDerivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,354 F1 · shares: On June 29, 2018, the Reporting Person was granted 20,594 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. F1 · price: On June 29, 2018, the Reporting Person was granted 20,594 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:14 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseSeries B Convertible Preferred Stock · Derivative | 12 | $1,000.00 Strike: $0.50 | $12,000.00 |
DisclosureSEC source: 0000905718-18-000580 · ende-matinas_fm4jun212018.xml · derivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12 Underlying: Common Stock · 24,000 shares Expires not disclosed F1 · derivative.exercise_date: On June 21, 2018, the Reporting Person purchased 12 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F1 · derivative.expiration_date: On June 21, 2018, the Reporting Person purchased 12 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. Read SEC document |
| March 30, 2018 Filed Apr 2, 2018 17:06 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 11,760 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000357 · ende_form4mar302018.xml · nonDerivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,760 F1 · shares: On March 30, 2018, the Reporting Person was issued 11,760 shares of common stock par value $.0001 per share which vest immediately upon grant. Read SEC document |
| December 14, 2017 Filed Feb 27, 2018 21:17 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantOption (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000905718-18-000281 · ende_fm4dec142017.xml · derivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-12-13 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on January 14, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| April 03, 2017 Filed Apr 21, 2017 16:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantOption (right to buy) · Derivative | 150,000 | $2.92 Strike: $2.92 | $438,000.00 |
DisclosureSEC source: 0000905718-17-000485 · ende_fm4apr32017.xml · derivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2017-04-03 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on April 30, 2017. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| April 03, 2017 Filed Jul 19, 2017 17:39 UTC Amendment | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantOption (right to buy) · Derivative | 150,000 | $2.92 Strike: $2.92 | $438,000.00 |
DisclosureSEC source: 0000905718-17-000708 · ende_fm4ajun2017.xml · derivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-04-03 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on April 30, 2017. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. F2 · derivative.expiration_date: Amended Form 4 being filed to correct option expiration date. Read SEC document |
| April 03, 2017 Filed Apr 3, 2019 16:35 UTC Amendment | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 12,201 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000323 · matinasbiofm4am_apr212017.xml · nonDerivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,201 F1 · shares: On April 3, 2017, the Reporting Person was issued 12,201 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vested immediately upon grant. These shares were omitted from the Reporting Person's original Form 4 filing on April 21, 2017, and also were omitted from nine Forms 4 filings filed by the Reporting Person after such filing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.